Home › Research › Down syndrome and Alzheimer's
The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy
Gholipour T, Mitchell S, Sarkis RA, Chemali Z.. Epilepsy & behavior : E&B, 2017-02-10
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Adult patients with Down syndrome (DS) are at higher risk of developing Alzheimer-type dementia and epilepsy. The relationship between developing dementia and the risk of developing seizures in DS is poorly characterized to date. In addition, treatment response and medication tolerability have not been rigorously studied. Methods We identified 220 patients with a diagnosis of DS and dementia. Those without a history of developing seizures (DD) were compared to patients with new-onset seizures (DD+S) after the age of 35. Electronic records were reviewed for demographics, seizure characteristics, cognitive status, and psychiatric comorbidities. Results Of the patients included for analysis, twenty-six out of 60 patients had new-onset seizures or developed seizures during the follow-up period (the DD+S group) with a median onset of 2.0years after the dementia diagnosis. Generalized tonic-clonic seizures were the most common seizure type (61.5% of DD+S). Sixteen (61.5%) patients were reported to have myoclonus. Levetiracetam was the most commonly used initial medication, with the majority (73%) of patients treated achieving partial or complete seizure control. The DD+S patients tended to have a similar burden of new-onset neuropsychiatric symptoms compared to the DD group. Discussion New-onset epilepsy seems to occur early in the course of dementia in DS patients. Patients generally respond to treatment. A great burden of neuropsychiatric symptoms is seen. Future studies need to explore the relationship between β-amyloid accumulation and epileptiform activity and attend to the care and needs of DS patients with dementia and seizures.
What this study adds
Evidence grade: Low
The record lists 220 participants. This review of patient records found that new-onset seizures tended to occur about two years after a dementia diagnosis in people with Down syndrome, and most patients treated with levetiracetam achieved partial or complete seizure control. Reported effect size: 61.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gholipour, T., Mitchell, S., Sarkis, R. A., & Chemali, Z. (2017). The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy. Epilepsy & behavior : E&B. https://doi.org/10.1016/j.yebeh.2016.12.014
Vancouver
Gholipour T, Mitchell S, Sarkis RA, Chemali Z. The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy. Epilepsy & behavior : E&B. 2017. doi:10.1016/j.yebeh.2016.12.014. PMID: 28109983.
BibTeX
@article{gholipour2017-28109983,
author = {Gholipour, T. and Mitchell, S. and Sarkis, R. A. and Chemali, Z.},
title = {{The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy}},
journal = {Epilepsy \& behavior : E\&B},
year = {2017},
doi = {10.1016/j.yebeh.2016.12.014},
pmid = {28109983},
url = {https://doi.org/10.1016/j.yebeh.2016.12.014}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Background Adult patients with Down syndrome (DS) are at higher risk of developing Alzheimer-type dementia and epilepsy.
- Those without a history of developing seizures (DD) were compared to patients with new-onset seizures (DD+S) after the age of 35.
- Results Of the patients included for analysis, twenty-six out of 60 patients had new-onset seizures or developed seizures during the follow-up period (the DD+S group) with a median onset of 2.0years after the dementia diagnosis.
- The DD+S patients tended to have a similar burden of new-onset neuropsychiatric symptoms compared to the DD group.
Why it matters
This review of patient records found that new-onset seizures tended to occur about two years after a dementia diagnosis in people with Down syndrome, and most patients treated with levetiracetam achieved partial or complete seizure control. It describes the clinical course and seizure treatment response but does not address curing or preventing Alzheimer's disease.
Study details
- Participants220
- Effect size61.5%
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Epilepsy & behavior : E&B) |
| Journal's citation record | 2 / 4 | Epilepsy & Behavior: journal h-index 154 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 220 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 2 / 6 | Cited 2.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Zeina N. Chemali: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28109983) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.